Diary - News
All news Transgene and BioInvent collaborate to develop multifunctional viruses for the treatment of solid tumors
Strasbourg (France) and Lund (Sweden), March 26, 2019, 8:30 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors and BioInvent International AB (OMXS: BINV), a biotech company focused on the discovery and development of novel immunoregulatory antibodies to treat cancer, announce the extension of their collaboration to co-develop multi-functional oncolytic viruses (OV) encoding for undisclosed antibodies sequences capable of treating a broad range of solid tumors.
